There is a lot of variation in how patients with acute myeloid leukemia (AML) react to the disease, and to its treatment. There are three main approaches to managing AML, and assessing the risks and benefits of each approach is crucial for making treatment decisions. Risk stratification involves assessing a patient’s age, health, and overall underlying conditions.
Andrew Krivoshik, MD, PhD, Oncology Therapeutic Area Head at Astellas Pharma, reviews treatment options for acute myeloid leukemia (AML) patients. Dr. Krivoshik states that, while patients traditionally receive…
Mikkael Sekeres, MD, director of the Leukemia Program and vice-chair for Clinical Research at the Cleveland Clinic Taussig Cancer Institute, discusses a phase 2 study of pevonedistat plus azacitidine…
Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX; Joshua Zeidner, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Eytan Stein, MD, Memorial…
In this interview, Yousef Zakharia, MD, shares thoughts on the topic of expanding acute myeloid leukemia (AML) treatment. Dr. Zakharia discusses up-to-date AML treatments from combination trials such…
Naval G. Daver, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, highlights findings from the randomized phase…
Naval G. Daver, MD, a professor and director of the Leukemia Research Alliance Program, MD Anderson Cancer Center, Houston, Texas, highlighted significant advancements in acute myeloid leukemia (AML)…
Raajit K. Rampal, MD, PhD, hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses a recent study on the use of APR-246 for the treatment of myelodysplastic syndrome…
